Caribou Biosciences

Caribou Biosciences (CRBU)

$4.36

-0.11

(-2.46%)

Live

Performance

  • $4.29
    $4.55
    $4.36
    downward going graph

    1.61%

    Downside

    Day's Volatility :5.71%

    Upside

    4.18%

    downward going graph
  • $4.05
    $13.19
    $4.36
    downward going graph

    7.11%

    Downside

    52 Weeks Volatility :69.29%

    Upside

    66.94%

    downward going graph

Returns

PeriodCaribou Biosciences
3 Months
-18.87%
6 Months
-50.17%
1 Year
-48.74%
3 Years
-72.61%

Highlights

Market Capitalization
293.3M
Book Value
$4.54
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.87
Wall Street Target Price
28.43
Profit Margin
0.0%
Operating Margin TTM
-794.21%
Return On Assets TTM
-18.38%
Return On Equity TTM
-33.34%
Revenue TTM
14.7M
Revenue Per Share TTM
0.24
Quarterly Revenue Growth YOY
31.5%
Gross Profit TTM
-68.4M
EBITDA
-114.8M
Diluted Eps TTM
-1.87
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.96
EPS Estimate Next Year
-2.36
EPS Estimate Current Quarter
-0.49
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Caribou Biosciences(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 552.06%

Current $4.36
Target $28.43

Company Financials

FY19Y/Y Change
Revenue
5.8M
-
Net Income
-23.4M
-
Net Profit Margin
-404.82%
-
FY20Y/Y Change
Revenue
12.4M
↑ 113.56%
Net Income
-34.3M
↑ 46.42%
Net Profit Margin
-277.55%
↑ 127.27%
FY21Y/Y Change
Revenue
9.6M
↓ 22.35%
Net Income
-66.9M
↑ 95.07%
Net Profit Margin
-697.26%
↓ 419.71%
FY22Y/Y Change
Revenue
13.9M
↑ 44.31%
Net Income
-99.4M
↑ 48.56%
Net Profit Margin
-717.79%
↓ 20.53%
Q4 FY21Q/Q Change
Revenue
-2.9M
↓ 172.77%
Net Income
-18.5M
↓ 11.9%
Net Profit Margin
638.53%
↑ 1165.91%
Q1 FY22Q/Q Change
Revenue
2.7M
↓ 192.05%
Net Income
-19.1M
↑ 3.3%
Net Profit Margin
-716.52%
↓ 1355.05%
Q2 FY22Q/Q Change
Revenue
4.2M
↑ 57.36%
Net Income
-26.7M
↑ 39.86%
Net Profit Margin
-636.86%
↑ 79.66%
Q3 FY22Q/Q Change
Revenue
3.3M
↓ 21.21%
Net Income
-26.6M
↓ 0.19%
Net Profit Margin
-806.75%
↓ 169.89%
Q4 FY22Q/Q Change
Revenue
3.7M
↑ 11.78%
Net Income
-27.0M
↑ 1.28%
Net Profit Margin
-731.01%
↑ 75.74%
Q1 FY23Q/Q Change
Revenue
3.5M
↓ 5.15%
Net Income
-28.0M
↑ 3.91%
Net Profit Margin
-800.8%
↓ 69.79%
FY19Y/Y Change
Total Assets
61.9M
-
Total Liabilities
13.1M
-
FY20Y/Y Change
Total Assets
36.0M
↓ 41.8%
Total Liabilities
18.2M
↑ 38.13%
FY21Y/Y Change
Total Assets
442.4K
↓ 98.77%
Total Liabilities
54.5K
↓ 99.7%
FY22Y/Y Change
Total Assets
373.8K
↓ 15.51%
Total Liabilities
72.9K
↑ 33.67%
Q4 FY21Q/Q Change
Total Assets
442.4M
↓ 4.24%
Total Liabilities
54.5M
↓ 5.26%
Q1 FY22Q/Q Change
Total Assets
446.0M
↑ 0.82%
Total Liabilities
74.2M
↑ 36.07%
Q2 FY22Q/Q Change
Total Assets
421.4M
↓ 5.52%
Total Liabilities
73.5M
↓ 0.97%
Q3 FY22Q/Q Change
Total Assets
398.8M
↓ 5.35%
Total Liabilities
74.7M
↑ 1.68%
Q4 FY22Q/Q Change
Total Assets
373.8M
↓ 6.28%
Total Liabilities
72.9M
↓ 2.43%
Q1 FY23Q/Q Change
Total Assets
347.5M
↓ 7.04%
Total Liabilities
69.2M
↓ 5.08%
FY19Y/Y Change
Operating Cash Flow
-32.0M
-
Investing Cash Flow
27.2M
-
Financing Cash Flow
172.0K
-
FY20Y/Y Change
Operating Cash Flow
-33.2M
↑ 3.78%
Investing Cash Flow
6.4M
↓ 76.63%
Financing Cash Flow
1.7M
↑ 908.72%
FY21Y/Y Change
Operating Cash Flow
-32.5M
↓ 2.1%
Investing Cash Flow
-176.4M
↓ 2872.23%
Financing Cash Flow
433.4M
↑ 24881.5%
FY22Y/Y Change
Operating Cash Flow
-91.0M
↑ 179.73%
Investing Cash Flow
-93.2M
↓ 47.14%
Financing Cash Flow
2.1M
↓ 99.51%
Q4 FY21Q/Q Change
Operating Cash Flow
-21.4M
↑ 42.91%
Investing Cash Flow
-174.0M
↑ 8913.52%
Financing Cash Flow
460.0K
↓ 99.86%
Q1 FY22Q/Q Change
Operating Cash Flow
-21.7M
↑ 1.33%
Investing Cash Flow
-72.1M
↓ 58.55%
Financing Cash Flow
990.0K
↑ 115.22%
Q2 FY22Q/Q Change
Operating Cash Flow
-21.9M
↑ 0.92%
Investing Cash Flow
-14.0M
↓ 80.62%
Financing Cash Flow
362.0K
↓ 63.43%
Q3 FY22Q/Q Change
Operating Cash Flow
-65.9M
↑ 201.39%
Investing Cash Flow
-8.3M
↓ 40.32%
Financing Cash Flow
2.0M
↑ 454.14%
Q4 FY22Q/Q Change
Operating Cash Flow
18.5M
↓ 128.07%
Investing Cash Flow
1.2M
↓ 114.03%
Financing Cash Flow
-1.2M
↓ 161.07%
Q1 FY23Q/Q Change
Operating Cash Flow
-27.9M
↓ 251.01%
Investing Cash Flow
20.7M
↑ 1669.49%
Financing Cash Flow
1.6M
↓ 234.04%

Technicals Summary

Sell

Neutral

Buy

Caribou Biosciences is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Caribou Biosciences
Caribou Biosciences
1.59%
-50.17%
-48.74%
-72.61%
-72.61%
Moderna, Inc.
Moderna, Inc.
-6.6%
-29.55%
-6.79%
114.56%
571.72%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.63%
0.01%
30.35%
23.26%
140.46%
Novo Nordisk A/s
Novo Nordisk A/s
-5.39%
23.69%
41.34%
146.71%
255.68%
Seagen, Inc.
Seagen, Inc.
-2.64%
57.03%
37.37%
30.74%
191.76%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.55%
6.52%
28.06%
22.79%
123.76%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Caribou Biosciences
Caribou Biosciences
NA
NA
NA
-1.96
-0.33
-0.18
0.0
4.54
Moderna, Inc.
Moderna, Inc.
10.88
10.88
0.0
-1.74
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.15
20.15
9.01
41.59
0.19
0.1
0.0
219.38
Novo Nordisk A/s
Novo Nordisk A/s
41.07
41.07
2.03
4.99
0.84
0.23
0.01
4.44
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.89
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
25.51
25.51
0.41
14.57
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Caribou Biosciences
Caribou Biosciences
Buy
$293.3M
-72.61%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$47.9B
571.72%
10.88
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.0B
140.46%
20.15
33.81%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$356.5B
255.68%
41.07
32.47%
Seagen, Inc.
Seagen, Inc.
Hold
$36.5B
191.76%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$85.1B
123.76%
25.51
35.4%

Institutional Holdings

  • Partner Fund Management LP

    8.17%
  • BlackRock Inc

    7.70%
  • State Street Corporation

    5.47%
  • Avidity Partners Management LP

    4.50%
  • Rokos Capital Management LLP

    4.48%
  • Vanguard Group Inc

    4.25%

Corporate Announcements

  • Caribou Biosciences Earnings

    Caribou Biosciences’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Caribou Biosciences
Employees
137
CEO
Dr. Rachel E. Haurwitz Ph.D.
Industry
Services

FAQs